Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc. - Common Stock (NQ:CNTX)

0.8699 +0.0199 (+2.34%)
Streaming Delayed Price Updated: 1:18 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 79,142
Open 0.8600
Bid (Size) 0.8623 (2)
Ask (Size) 0.8699 (2)
Prev. Close 0.8500
Today's Range 0.8480 - 0.8699
52wk Range 0.4900 - 2.590
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) Posts Wider Q2 2025 Loss Amid Continued Pipeline Progress
Context Therapeutics reports Q2 2025 loss of $0.09 per share, missing estimates. Pipeline advances with Phase 1 trials for CTIM-76 and CT-95, but shares drop 14.3% post-earnings. Cash runway extends to... 
Via Chartmill

Performance

YTD
-26.9%
-26.9%
1 Month
-0.3%
-0.3%
3 Month
+50.7%
+50.7%
6 Month
+9.4%
+9.4%
1 Year
-58.2%
-58.2%

More News

Read More
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Announces Chief Medical Officer Transition
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
From Context Therapeutics Inc.
Via GlobeNewswire
Unusual volume stocks in Friday's session
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday.
Via Chartmill
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
From Context Therapeutics Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-03-25: top gainers and losers in today's session.
Via Chartmill
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
From Context Therapeutics Inc.
Via GlobeNewswire
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Context Therapeutics Inc. - Common Stock publicly traded?
Yes, Context Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Context Therapeutics Inc. - Common Stock trade on?
Context Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Context Therapeutics Inc. - Common Stock?
The ticker symbol for Context Therapeutics Inc. - Common Stock is CNTX on the Nasdaq Stock Market
What is the current price of Context Therapeutics Inc. - Common Stock?
The current price of Context Therapeutics Inc. - Common Stock is 0.8699
When was Context Therapeutics Inc. - Common Stock last traded?
The last trade of Context Therapeutics Inc. - Common Stock was at 09/17/25 01:18 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.